Ferinject
[CAS# 9007-72-1]

Identification

• Classification: API >> Other chemicals
• Name: Ferinject
• Synonyms: Ferric carboxymaltose; Injectafer; 4-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanoate iron(3+) oxygen(2-) hydroxide hydrate
• Molecular Formula: C₂₄H₄₄FeO₂₅^-
• Molecular Weight: 788.44
• CAS Registry Number: 9007-72-1
• EC Number: 813-933-0
• SMILES: C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC(C(CO)O)C(C(C(=O)[O-])O)O)CO)CO)O)O)O)O.O.[OH-].[O-2].[Fe+3]

Safety Data

• Hazard Symbols: GHS07;GHS08 Warning
• Risk Statements: H315-H319-H335-H361-H373
• Safety Statements: P203-P260-P261-P264-P264+P265-P271-P280-P302+P352-P304+P340-P305+P351+P338-P318-P319-P321-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Skin irritation	Skin Irrit.	2	H315
Eye irritation	Eye Irrit.	2	H319
Reproductive toxicity	Repr.	2	H361
Specific target organ toxicity - repeated exposure	STOT RE	2	H373
Specific target organ toxicity - single exposure	STOT SE	3	H335

Discovery and Applications

Fehling injection, also known as Fehling's solution, was developed by German chemist Hermann von Fehling in the mid-19th century. Fehling originally devised the solution as a qualitative test for the presence of reducing sugars in analytical chemistry.

Fehling injection is primarily used in laboratory settings as a reagent for detecting reducing sugars, such as glucose and fructose, in various chemical reactions. It consists of two separate solutions, Fehling A (aqueous copper(II) sulfate) and Fehling B (aqueous sodium potassium tartrate and sodium hydroxide), which are mixed in equal volumes before use. When heated with a solution containing reducing sugars, Fehling's solution undergoes a characteristic color change from blue to brick-red, indicating the presence of reducing sugars.

References

2024. No longer to be ignored: Hypophosphatemia following intravenous iron administration. Reviews in Endocrine and Metabolic Disorders, 25(6).
DOI: 10.1007/s11154-024-09926-5

2024. Randomised Controlled Trial Evaluating the Impact of Intravenous Iron (ferric carboxymaltose) Supplementation Among Epithelial Ovarian Cancer Patients with Anemia. Indian Journal of Surgical Oncology, 15(4).
DOI: 10.1007/s13193-024-02149-9

2024. Efficacy of Intravenous Ferric Carboxymaltose in Heart Failure Patients with Iron Deficiency Anemia: A Meta-analysis of 6271 Patients. Clinical Drug Investigation, 44(11).
DOI: 10.1007/s40261-024-01401-y